Archives hepatitis-c

by in
Entry Author Date Location
FDA Approves Vertex’s Two-Drug Combo For Cystic Fibrosis 07/02/15 Boston
Vertex Teams up With Durham’s Parion in $80M Lung Drug Deal 06/04/15 Boston
East Coast Biotech Roundup: Bluebird, Sarepta, Synlogic & More 05/22/15 Boston
West Coast Biotech Roundup: Orexigen, Denali, Nant, ASCO & More 05/15/15 San Diego
FDA Panel Backs Vertex’s Two-Drug Combo For Cystic Fibrosis 05/12/15 Boston
The Innovation Challenge: Assessing BioPharma Startups 05/04/15 Seattle
Reflections on the “Build to Buy,” Part 2: The Applicability Problem 04/30/15 National
East Coast Biotech Roundup: Cellectis, Bristol, What’s Hot & More 04/13/15 Boston
Stop the Bleeding: Can Gene Therapy Finally Cure Hemophilia? 03/23/15 National
East Coast Biotech Roundup: Sync Project, Epizyme, Bristol & More 03/16/15 Boston
AbbVie Snaps up Pharmacyclics, Pays Whopping $21B For Cancer Drug 03/05/15 National
East Coast Biotech Roundup: Vertex, Syndax, Build-to-Buy Deals & More 02/20/15 Boston
Vertex Buys Spine Drug on the QT As Part of Its Post-Hep C Makeover 02/20/15 Boston
West Coast Biotech Roundup: Dendreon, Invitae, Juno, Regulus & More 02/12/15 Seattle
Gilead Exec: More Value in Quick Hep C Cure than Cancer Treatments 02/10/15 San Francisco
East Coast Biotech Roundup: Hamburg, Merck, Annovation, WaVe & More 02/09/15 Boston
FDA’s Hamburg Stepping Down With Biopharma Turnaround as Her Legacy 02/05/15 National
East Coast Biotech Roundup: Alnylam, Stock Offerings, Curis, & More 01/23/15 Boston
J.P. Morgan 2015: Notes, Thoughts, And Conversations From the Vortex 01/16/15 National
East Coast Biotech Roundup: Foundation, Biogen, Moderna, & Lots More 01/16/15 Boston
West Coast Biotech Roundup: Tobira, Novartis, NantCell, & More 01/15/15 San Francisco
West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More 01/08/15 San Francisco
Don’t Get Comfortable: 5 Biopharma Flashpoints to Consider in 2015 01/06/15 National
Hepatitis C Commercial Game Theory 01/01/15 National
West Coast Biotech Roundup: Gilead/AbbVie, Juno, Auspex, Bina & More 12/23/14 San Francisco
Enanta Pockets $75M As AbbVie, Gilead Hep C Battle Begins 12/19/14 Boston
Prescription Drug Pricing: The Fine Line Between Value and Greed 12/02/14 Boston
After Unlikely Idenix Sale, Renaud Jumps to RaNA to Outfox Junk DNA 12/01/14 Boston
West Coast Biotech Roundup: Gilead, Juno, Hutch, Fibrogen & More 11/20/14 Seattle
With Gilead’s $125M Purchase, FDA Voucher Program Gains Momentum 11/19/14 San Francisco
Page 1 of 9 next page »